New drug cocktail targets Hard-to-Treat myeloma

NCT ID NCT06876142

Terminated Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 34 times

Summary

This study tests two oral drugs, mirdametinib and sirolimus, in people with relapsed or refractory multiple myeloma that has specific RAS gene mutations. The trial has two phases: first to find a safe dose, then to see how well the combo works. Up to 54 adults will take the drugs daily in 4-week cycles for a year, with follow-up for 4 more years. The study is currently suspended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mirdametinib and sirolimus
What this could lead to: If it works, this could offer a new treatment option for people with multiple myeloma that has not responded to other therapies and has specific gene changes.
What could go wrong: This is an early-phase trial (1b/2) with only 54 participants, currently suspended. The combination may cause side effects or fail to show benefit. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.